Chongqing Lummy Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Chongqing Lummy Pharmaceutical heeft een totaal eigen vermogen van CN¥2.1B en een totale schuld van CN¥394.4M, wat de schuld-eigenvermogensverhouding op 18.7% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥3.0B en CN¥929.3M.

Belangrijke informatie

18.7%

Verhouding schuld/eigen vermogen

CN¥394.41m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥1.09b
Aandelen	CN¥2.11b
Totaal verplichtingen	CN¥929.27m
Totaal activa	CN¥3.04b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

Nov 15

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Oct 29

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

Oct 01

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Oct 01

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥1.8B ) 300006 } overtreffen de korte termijn passiva ( CN¥781.9M ).

Langlopende schulden: De kortetermijnactiva 300006 ( CN¥1.8B ) overtreffen de langetermijnschulden ( CN¥147.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 300006 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 300006 is de afgelopen 5 jaar gedaald van 66% naar 18.7%.

Schuldendekking: De schuld van 300006 wordt goed gedekt door de operationele kasstroom ( 56.7% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 300006 op haar schulden goed worden gedekt door EBIT.

Chongqing Lummy Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0 in 3Q 2023)

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.048 loss in 2Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven